Protocol Ledger

NCT07235917 · Phase II · RECRUITING

A Study to Investigate Mibavademab in Adult Women With Functional Hypothalamic Amenorrhea

Interventional Phase II clinical trial protocol NCT07235917 sponsored by Regeneron Pharmaceuticals in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-03-11 Enrollment: 34 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07235917
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)34 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07235917
Protocol FieldVerified Registry Value
NCT IdentifierNCT07235917
Consolidated Lead SponsorRegeneron Pharmaceuticals
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment34 participants (ESTIMATED)
Registered Start Date2026-03-11
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07235917
Hospital Research SiteLocationSite Profile
Yale Cancer Center and Smilow Cancer HospitalNew Haven, CTOpen Hospital Dossier ->
Mayo Clinic FloridaJacksonville, FLOpen Hospital Dossier ->
Oregon Health and Science University Knight Cancer InstitutePortland, OROpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Regeneron Pharmaceuticals across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI